Literature DB >> 19656783

Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin.

Francis F Arhin, Ingrid Sarmiento, Thomas R Parr, Gregory Moeck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19656783     DOI： 10.1093/jac/dkp286

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  12 in total

1.  Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.

Authors:  Adam Belley; Geoffrey A McKay; Francis F Arhin; Ingrid Sarmiento; Sylvain Beaulieu; Ibthihal Fadhil; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

2.  Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.

Authors:  Gengrong Lin; Glenn Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

3.  Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.

Authors:  Ronald N Jones; Greg Moeck; Francis F Arhin; Michael N Dudley; Paul R Rhomberg; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Host-guest chemistry of the peptidoglycan.

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

Review 5.  Oritavancin: a review in acute bacterial skin and skin structure infections.

Authors:  Yahiya Y Syed; Lesley J Scott
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 6.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 7.  New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.

Authors:  Matthew P Crotty; Tamara Krekel; C A Burnham; David J Ritchie
Journal:  J Clin Microbiol       Date:  2016-03-09       Impact factor: 5.948

8.  Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.

Authors:  Lala M Dunbar; Joe Milata; Ty McClure; Margaret M Wasilewski
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 9.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

10.  Locations of the hydrophobic side chains of lipoglycopeptides bound to the peptidoglycan of Staphylococcus aureus.

Authors:  Sung Joon Kim; Kelly S E Tanaka; Evelyne Dietrich; Adel Rafai Far; Jacob Schaefer
Journal:  Biochemistry       Date:  2013-05-08       Impact factor: 3.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.